TheraCryf plc announced positive top-line data from the first toxicology species in its lead Ox-1 addiction program, with the drug well-tolerated at doses 100 times the expected human therapeutic use, exceeding FDA safety margin requirements. Clinical trial enabling work is progressing ahead of schedule, with manufacturing scale-up complete and a patent application submitted for improvements. The company is on track to submit its clinical trial application data in 2026, a significant value inflection point, and is attracting interest from potential partners, with Phase 1 clinical stage assets attracting up-front payments of US$26 million to US$49 million.
